CHRNEkso Bionics Holdings, Inc. Common Stock
The schedule
- Thu15Oct
Expected timeline for FDA clearance of new exoskeleton stroke and multiple sclerosis indications, pivoting from the $14.80 base level.
- Tue10Nov
Management addresses late-year commercial adoption metrics and forecasts the 2027 cash burn trajectory, anchoring from a $16.50 price point.
- Tue12Jan
Anticipated seasonal window for a secondary equity offering to fortify the balance sheet for 2027 manufacturing and sales expansion, starting from $14.00.
- Thu4Mar
Full-year results and initial 2027 revenue outlook. With expectations heavily reset and shares trading around $11.50, the setup shifts to a more favorable risk/reward profile.
Past
- Wed5Aug
Ekso Bionics reports Q2 results with shares trading at an overbought $17.20, leaving little room for execution missteps. We anticipate a sell-the-news reaction if guidance fails to decisively raise the bar.